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Abstract
Background: There is now good evidence about the management options for pregnant women with a
breech presentation (buttocks or feet rather than head-first) at term; external cephalic version (ECV) –
the turning of a breech baby to a head-down position and/or planned caesarean section (CS). Each of these
options has benefits and risks and the relative importance of these vary for each woman, subject to her
personal values and preferences, a situation where a decision aid may be helpful.
Decision aids are designed to assist patients and their doctors in making informed decisions using
information that is unbiased and based on high quality research evidence. Decision aids are non-directive
in the sense that they do not aim to steer the user towards any one option, but rather to support decision
making which is informed and consistent with personal values.
The ECV decision aid was developed using the Ottawa Decision Support Framework, including a
systematic review of the evidence about the benefits and risks of the options for breech pregnancy. It
comprises an audiotape with a supplementary booklet and worksheet, a format that can be taken home
and discussed with a partner. This project aims to evaluate the ECV decision aid for women with a breech
presenting baby in late pregnancy.
Study design: We aim to evaluate the effectiveness of the decision aid compared with usual care in a
randomised controlled trial in maternity hospitals that offer ECV. The study group will receive the decision
aid in addition to usual care and the control group will receive standard information on management
options for breech presentation from their usual pregnancy care provider. Approximately 184 women
with a single breech-presenting baby at greater than 34 weeks gestation and who are clinically eligible for
ECV will be recruited for the trial.
The primary outcomes of the study are knowledge, decisional conflict, anxiety and satisfaction with 
decision-making that will be assessed using self-administered questionnaires. The decision aid is not 
intended to influence either the uptake of either ECV or planned CS, however we will monitor health 
service utilisation rates and maternal and perinatal outcomes.
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Background
Breech presentation
Breech presentation occurs when a baby presents with the
buttocks or feet rather than head first (cephalic presenta-
tion). As breech presentation is related to both fetal size
and gestational age, the incidence decreases as pregnancy
progresses to 3–4% by full-term[1,2]. Decades of contro-
versy over the safe management of breech birth at term
has recently been resolved by an international multicentre
randomised controlled trial (the Term Breech Trial, TBT)
of planned vaginal breech birth versus planned caesarean
section (CS)[3]. This trial was stopped prematurely
because of overwhelming benefit favouring planned CS,
with a relative risk of 0.33 (95%CI 0.19–0.56) for perina-
tal/neonatal mortality or serious neonatal morbidity[3].
The TBT results were subsequently added to two small tri-
als in a Cochrane Systematic Review[4]. The reduction in
perinatal morbidity and mortality was even more pro-
nounced when the analyses were limited to births in low
perinatal mortality countries, such as Australia (RR 0.13;
95%CI 0.05–0.31)[4]. However, planned caesarean sec-
tion was associated with increased maternal morbidity
(RR 1.29; 95% CI 1.03–1.61)[4].
These results have dramatically altered a woman's options
if she has a breech presentation at term, as CS is now
offered as the safest and in many institutions the only,
management option. This change has occurred rapidly:
The TBT was published in October 2000 and the rate of
vaginal breech birth in NSW declined from 17% in 1999
to 14% in 2000 and 4.5% in 2001[5]. However, while
safer than vaginal breech birth, planned CS is not without
risk[6,7]. Complications include increased risk of pulmo-
nary embolism, infection [8-10], bleeding[9,11], damage
to bladder and bowel[12], slower recovery from the
birth[12,13], longer hospitalisation[11], respiratory diffi-
culties for the baby [14-16], delayed bonding and breast-
feeding[17,18], and compromise of future obstetric
performance[17,19-21]. Therefore, the best way to avoid
the increased risks associated with term breech presenta-
tion is to avoid it altogether, and this is possible via exter-
nal cephalic version.
External cephalic version (ECV) of the breech-presenting 
baby
External cephalic version (ECV) is the turning of a breech
baby to a cephalic presentation. Systematic review of six
well designed randomised controlled trials demonstrates
that among women with breech presentation in late preg-
nancy, ECV reduces both breech presentations in labour
(RR = 0.42, 95%CI 0.35–0.50) and caesarean sections (RR
= 0.52. 95%CI 0.39–0.71)[22].
Despite clear evidence of effectiveness and potential ben-
efit, many women decline ECV for a variety of reasons.
Both breech presentation and ECV success rates are
strongly influenced by parity, with success rates reported
as low as 25% for women having their first baby[23]. For
other women, the inconvenience of extra clinic visits and
the need for an IV line for tocolysis may be deter-
rents[24,25]. Approximately 35% of women undergoing
ECV report mild or moderate discomfort during the pro-
cedure[26]. Other complications of ECV are either
uncommon (e.g. transient fetal bradycardia [12%] or diz-
ziness and palpitations from tocolysis [4%]) or rare
(<1%) (e.g. profound fetal bradycardia, preterm labour,
premature rupture of membranes and bleeding)[26]. The
remote possibility of emergency CS (e.g. because of pla-
cental abruption following the procedure) is also recog-
nised. For these and other reasons, women may have a
preference for planned CS. An Australian study of decision
making for CS conducted in 1996 included 62 women
with a breech presentation[27]. Of these, 39 women were
offered ECV and 12 (31%) "decided against it". Further,
37 women were offered vaginal breech birth but 14 (38%)
women chose CS[27].
Women's views and information needs
To obtain data on Australian women's views and informa-
tion needs about ECV we undertook a cross-sectional
study of women's knowledge, attitudes and decision-mak-
ing preferences for the management of breech presenta-
tion[28]. Of 174 pregnant women respondents (97%
response rate), almost 90% preferred vaginal delivery but
only 66% had heard of ECV. After a brief written explana-
tion of ECV 39% would choose ECV, 22% were unsure
and 39% would not choose ECV. The reasons for not
choosing ECV included concerns about safety for the baby
(13%), that ECV doesn't guarantee vaginal delivery (12%)
and preference for a caesarean section anyway (8%).
Importantly, 95% of pregnant women wanted involve-
ment in decision-making about breech presentation.
Patient participation in clinical decision making
It is now recognised that many consumers want to partic-
ipate in clinical decisions about their health [29-31].
NHMRC states that good medical decision making should
take account of patients' preferences and values[29], thus
challenging health professionals to find ways of involving
consumers/patients in decisions about their health. Yet
little is currently known about how this can be effectively
achieved. One method is to provide information to con-
sumers about treatment options and likely outcomes. To
assist informed decision making, such information must
be unbiased and based on current, high quality, quantita-
tive research evidence. However, patient information
materials are often outdated, inaccurate, omit relevant
data, fail to give a balanced view and ignore uncertainties
and scientific controversies[31,32].BMC Pregnancy and Childbirth 2004, 4:26 http://www.biomedcentral.com/1471-2393/4/26
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To help patients take a more active role in important clin-
ical decisions, decision aids based on latest research evi-
dence are being developed by several centres (for example
the Ottawa Health Decision Center in Canada and the
Foundation for Informed Medical Decision Making in the
USA). Decision aids are defined by the Cochrane Collab-
oration[33] as "interventions designed to help people
make specific and deliberative choices among options by
providing (at minimum) information on the options and
outcomes relevant to the person's health status". Addi-
tional strategies may include providing: information on
the disease/condition; the probabilities of outcomes tai-
lored to a person's health risk factors; an explicit values
clarification exercise; examples of others' decisions; and
guidance and coaching in the steps of decision mak-
ing[33]. Decision aids are non-directive in the sense that
they do not aim to steer the user towards any one option,
but rather to support decision making which is informed,
consistent with personal values and acted upon[34]. Deci-
sion aids have been found to improve patient knowledge
and create more realistic expectations, to reduce deci-
sional conflict (uncertainty about the course of action)
and to stimulate patients to be more active in decision
making without increasing anxiety[35].
Currently only 38 decision aids worldwide have been
developed and carefully evaluated in randomised control-
led trials[33,35]. Examples include hormone replacement
therapy for postmenopausal women, anticoagulants for
atrial fibrillation, PSA testing for prostate cancer and pre-
natal genetic screening. Until the publication of a series of
evidence-based leaflets in the United Kingdom in
2002[36,37], no decision aids have been developed and
evaluated in the context of obstetric care, although this is
an area in which consumers are known to want to partic-
ipate actively in decision making[38]. An Australian sur-
vey of 790 postpartum women found not having an active
say in decisions about pregnancy care was associated with
a sixfold increase in dissatisfaction among primiparas and
a fifteen fold increase among multiparas[38]. Similarly in
the UK, postpartum women rated an explanation of pro-
cedures and involvement in decision making as most
important to satisfaction with care[39]. Further, neither
obstetricians nor midwives appreciated the importance to
women of "being told the major risks for each
procedure"[39].
Decision making and breech presentation
The management of breech presentation is a clinical deci-
sion that fulfils Eddy's criteria for a decision in which
patients' values and preferences should be included[40].
The outcomes for the breech management options (ECV
and planned CS), and women's preferences for the rela-
tive value of benefits compared to risks are variable and
could result in decisional conflict. For such a clinical deci-
sion, a decision aid would be expected to improve patient
knowledge and create more realistic expectations, to
reduce decisional conflict and to stimulate patients to be
more active in decision making without increasing
anxiety[35].
Development and pilot-testing of the decision aid
In 2002 we developed an evidence-based decision aid for
women with a breech presentation in late pregnancy. In
developing the decision aid we utilised the NHMRC
guideline "How to prepare and present information for
consumers of health services"[41] (developed in 1999 by
a team led by Dr Barratt), and the Ottawa framework
established and rigorously tested by the Ottawa Health
Decision Center[34]. The decision aid includes a Work-
book, Audiotape/CD and Worksheet. The workbook
highlights key points (similar to a slide presentation) and
the audiotape/CD connects these points in a narrative for-
mat, providing more detail than the workbook. The work-
sheet is a one-page sheet to be completed by the woman
to record her decision making steps, to list any questions
she needs answered before deciding, and to indicate her
preferred role in this decision (she should decide, her
health care provider should decide, they should decide
together). Most importantly, the DA was designed to be
non-directive in that it did not aim to steer the user
towards any one option or increase or decrease interven-
tion rates but rather act as an adjunct to care
The decision aid was designed for women to use at home
or in the clinical setting, and takes about 30 minutes to
complete. The aural component is available on both audi-
otapes and CDs so participants can choose which they
prefer to use. After working through the decision aid, the
woman brings her completed worksheet to her next ante-
natal appointment to discuss her provisional decision
with her health care provider before arriving at her final
decision. The worksheet is also useful for the practitioner,
who can see rapidly from it what evidence the patient has
considered, what her values and preferences on this topic
are and which way she is leaning in her decision.
The decision aid was developed, pilot tested and revised
with extensive consumer involvement, as outlined in the
NHMRC guideline on preparing information for consum-
ers[41]. Content was largely driven by consumers' ques-
tions and information needs as determined from the
cross-sectional study[28] and from the process of drafting,
pilot testing and re-drafting.
A number of draft decision aids (including workbook,
audiotape/CD script, and worksheet), were developed
and each subjected to pilot testing and revision as we
obtained feedback. The process of testing and revising
started with the project group. The next phase included aBMC Pregnancy and Childbirth 2004, 4:26 http://www.biomedcentral.com/1471-2393/4/26
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review by a group of national and international content
experts, including decision aid experts, obstetricians, mid-
wives, perinatal epidemiologists and psychologists. Once
we were convinced that the content was accurate the deci-
sion aid was pilot-tested amongst consumers. There were
several rounds of consumer review and refinement. We
pilot-tested with members of consumer organisation
(Maternity Alliance) and in a convenience sample of preg-
nant and recently pregnant women. The next draft was
pilot-tested amongst pregnant women attending the ante-
natal clinic, who may or may not have had a breech pres-
entation. And finally we formally pilot tested the decision
aid with women who had a breech presentation in late
pregnancy and were at the point of decision making.
Pilot-testing results included: 95% of participants found
the decision aid clear and easy to understand and 80%
thought there was enough information for them to make
a decision. Over 90% found it very helpful and nearly all
women would recommend it to others. After reviewing
the decision aid, women experienced a significant
increase in their knowledge scores, less anxiety, had no
difficulty making decisions and were satisfied with their
decision.
This study aims to evaluate the ECV Decision Aid for
women with a breech-presenting baby in late pregnancy.
The decision aid is based on the most recently available
evidence and will be evaluated to assess the impact on
women's satisfaction with decision-making, knowledge,
anxiety and pregnancy outcomes. If successful, the results
could be applied to a improve consumer information and
participation in clinical decisions across a wide spectrum
of pregnancy care issues.
Methods
Specific aim
To compare the relative effectiveness of the decision aid
with standard care in relation to women's knowledge,
expectations, satisfaction with and participation in deci-
sion making, anxiety and decisional conflict. Secondary
outcomes will include service utilisation and perinatal
outcomes.
Hypotheses
The primary hypotheses of the study are:
Use of the ECV decision aid by women with a singleton
breech-presenting infant in late pregnancy
1. increases knowledge about breech presentation and the
management options
2. reduces decisional conflict (uncertainty about the
course of action)
3. increases satisfaction with decision making
4. reduces anxiety
The secondary hypotheses of the study are:
Use of the ECV decision aid by women with a singleton
breech-presenting infant in late pregnancy does not
influence
1. uptake of ECV
2. the proportion of women having a planned caesarean
section for breech presentation at term
3. maternal and infant outcomes
Study design
We will use a randomised trial with the following study
groups to assess the impact of the decision aid:
Group 1: Usual care (usual antenatal care provider coun-
selling on the management of breech presentation)
Group 2: Usual care + Decision aid with review by a
research midwife
As randomisation will be done at the individual level,
there is a risk of contamination of the usual care group if
the usual care provider also reviews the decision aid with
women in the study group. Therefore the decision aid will
be reviewed with a research midwife and the usual ante-
natal care providers will be blinded to the exact content
and format of the decision aid.
Setting
Australian obstetric hospitals that offer external cephalic
version.
Participants/eligibility criteria
Women with a single breech-presenting baby at ≥ 34
weeks gestation and who are clinically eligible for ECV
will be invited to participate in the trial.
Exclusion criteria are therefore those for ECV and include
women presenting with a breech in labour, multiple preg-
nancies, previous CS, severe fetal anomaly, ruptured
membranes and indications for CS anyway. The decision
aid will be produced in English and will be designed to be
simple and accessible for women with low levels of liter-
acy. The use of audiotapes and graphics will further aid
comprehension and ensure that, as far as possible, women
with low English literacy need not be excluded.BMC Pregnancy and Childbirth 2004, 4:26 http://www.biomedcentral.com/1471-2393/4/26
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Procedures, recruitment, randomisation and collection of 
baseline data
The study procedure will draw upon the usual schedule of
antenatal visits becoming weekly in late pregnancy and
the usual management of a breech-presentation in the late
pregnancy (Figure 1). Women diagnosed with a breech-
presenting baby at ≥ 34 weeks gestation will be asked to
participate. The research midwife will explain the trial and
obtain informed consent, collect baseline data and ran-
domly allocate (using telephone randomisation) women
to study or control groups. This is only a minor deviation
from current practice. As women of child-bearing age are
known to be very mobile, participants will be asked to
provide alternate contact details (eg friend or relative) to
enhance subsequent follow-up. Private obstetricians will
be asked to offer their patients participation in the study.
Those interested will be requested to come to the antena-
tal clinic for randomisation and recruitment. The private
obstetrician will provide usual care.
Intervention
The study group will receive the decision aid (workbook,
tape or CD, and worksheet) and the control group will
receive standard information on management options for
breech presentation from their usual carer. The study
group will be given the opportunity to work through the
decision aid while in the antenatal clinic and/or to take
home, which ever is most convenient. Many women will
also want to discuss the decision with their partner. This
pragmatic approach aims to assess the decision aid under
the conditions most likely to be applied in real practice. At
the next antenatal visit, women in the study group will
review their decision aid worksheet and any questions
with the research nurse.
Follow-up 1
All women will be given a follow-up questionnaire to
complete prior to their next antenatal clinic visit (see Out-
come Measures below for more detail). All women choos-
ing ECV will be given the opportunity to discuss the
procedure with the obstetrician providing the service. This
discussion is likely to include some of the probabilistic
information in the decision aid but will occur after the fol-
low-up questionnaire and will not influence the outcome
measures.
Follow-up 2
At 12–16 weeks post-partum all participants will be
mailed a second follow-up questionnaire. This will assess
women's satisfaction with their decision and the decision
making process when the events are past and the out-
comes known. (See Outcome Measures below for more
Schema of ECV decision aid trial Figure 1
Schema of ECV decision aid trial
Schema of ECV Decision Aid trial  Timing (data collection) 
Identification of breech presentation from routine antenatal visit   (≥34 weeks gestation) 
↓ ↓ ↓ ↓
Referral to research midwife (RM) –  
Who will check eligibility, recruit, obtain consent and randomise women 
↓ ↓ ↓ ↓
Study group  
ECV Decision Aid (DA) 
↓ ↓ ↓ ↓
Control group 
Usual Care 

│     (Baseline questionnaire) 
  
↓ ↓ ↓ ↓↓ ↓ ↓ ↓
Attend antenatal clinic 
→ review DA with RM    
↓ ↓ ↓ ↓
Attend antenatal clinic 
→ meet with RM    
↓ ↓ ↓ ↓
 Next routine antenatal visit     
(1 week later) 
(1
st follow-up questionnaire) 
Mailed questionnaire  Mailed questionnaire  12-16 weeks postpartum 
(2
nd follow-up questionnaire) BMC Pregnancy and Childbirth 2004, 4:26 http://www.biomedcentral.com/1471-2393/4/26
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detail). Questionnaires will be mailed with reply paid
envelopes, with up to two reminder telephone prompts to
non-responders.
Blinding and contamination
As in many obstetric interventions double blinding is vir-
tually impossible. The main outcomes of this study are
self-reported and the women are clearly not blinded to
their treatment allocation. However, we will institute a
number of measures aimed at keeping antenatal staff
blind to the treatment allocation and preventing contam-
ination of the control group:
• Women will review the decision aid with the research
midwife and complete the first questionnaire (primary
outcome measures) prior to their next antenatal
consultation
• Usual antenatal care providers will be blinded to the
content and format of the decision aid
• Regular in-service (educational training) for the antena-
tal care providers to explain the trial protocol and to make
clear the potential effect of unmasking or contamination.
• Monitoring decision aid distribution and keeping them
locked up and only accessible by the research midwife
• Asking participants not to reveal their treatment alloca-
tion, or share their decision aid material with antenatal
staff or other women. If participants do not want to keep
their decision aid they will be asked to return it.
• Monitoring the "usual care" (control) arm by conduct-
ing a run-in period in which women found to have a
breech presentation will be asked to complete the 1st fol-
low-up questionnaire. Thus we will have a baseline record
of knowledge about ECV, anxiety and decisional conflict
about the decision and satisfaction with the decision
before the DA is in use. Comparison of the data obtained
from this run-in period and the control arm will allow us
to judge whether, and to what extent, contamination has
occurred.
Outcome measures
Baseline data collection
Brief baseline data will be collected to assess comparabil-
ity of the study groups. The baseline assessment will
include age, parity, brief socio-demographic data, highest
level of education achieved, knowledge and anxiety as
assessed by the state component of the short Spielberger
anxiety scale[42].
Primary outcomes
The effectiveness of risk communication to aid patient
decision making is best assessed by a combination of cog-
nitive, affective and behavioural outcomes[43]. Thus the
primary outcomes of the this study will be
• cognitive: change in knowledge and realistic expecta-
tions of the management options and possible benefits
and risks of each option
• affective: anxiety, satisfaction with the decision, partici-
pation in decision-making and the amount of decisional
conflict (uncertainty about which course of action to
choose) experienced
• behavioural: actual decision taken and acted upon (see
secondary outcomes)
Measures of knowledge and realistic expectations about
options for the management of breech presentation and
the benefits and risks of ECV will be specific to this
project. Thus we will need to develop, and test these meas-
ures as part of the project.
Anxiety will be measured by the state component of the
short Spielberger anxiety scale which has been extensively
used and validated[42]. We do not anticipate the decision
aid will increase women's anxiety but it is nevertheless
important to document any increase or decrease in anxi-
ety attributable to the decision aid.
Satisfaction with the decision will be assessed using the
Satisfaction with Decision Scale. Satisfaction with Deci-
sion Scale (a very brief six item scale with high reliability)
was developed specifically to assess satisfaction with
health care decisions[44].
Participation in decision-making will be ascertained using
the five-item Degner Control Preferences Scale[45]. This
allows respondents to specify the degree of control in
decision-making they wish to assume with their doctor.
Decisional conflict will be assessed by the Decisional
Conflict Scale which has established reliability, good psy-
chometric properties and is short (16 items)[46]. It has
been used to evaluate a range of decision aids[35].
Because the decision about ECV must be made within a
short timeframe, the outcomes will be measured as soon
as practical after the consultation in which the ECV deci-
sion was made – prior to the next antenatal visit. For the
primary outcomes this will be within one week of the
decision being made (Figure 1, 1st follow-up).BMC Pregnancy and Childbirth 2004, 4:26 http://www.biomedcentral.com/1471-2393/4/26
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Satisfaction with the decision and anxiety will be meas-
ured again at 12–16 weeks postpartum as the last weeks of
pregnancy and the week after birth are associated with a
reduction in state anxiety[47]. We are interested to explore
whether women's views of the decision making process,
and the decision they ultimately made, may change with
time to reflect on the experience (Figure 1, 2nd follow-up).
Secondary outcomes
The aim of the decision aid is to assist patient decision
making, and not to influence the direction of the decision
taken. Nevertheless, we think it is important to collect
service utilisation and pregnancy outcome data so we will
record and compare the numbers of ECVs undergone and
ECV success rate in both arms of the study, as well as
recording and comparing rates of pregnancy complica-
tions and perinatal outcomes. Data on ECVs are already
prospectively collected for quality assurance, these
include fetal lie, parity, success rates and complications.
Other perinatal outcomes will be obtained (with
informed consent) from the existing computerised obstet-
ric database. These outcomes include mode of delivery
(vaginal, emergency or planned CS), enrolment to deliv-
ery interval, gestational age, birthweight, Apgar scores,
perinatal deaths, Neonatal Intensive Care Unit admission,
maternal haemorrhage (antepartum or postpartum) and
length of stay.
Statistical issues
Sample size
Sample size calculations for the trial (significance 0.05,
power 0.8) were determined using the mean difference we
would like to detect in women's decisional conflict scores
and knowledge of options and outcomes. Compared with
usual care, decisional conflict was shown in the most cur-
rent systematic review to be significantly reduced by deci-
sion aids; the meta-analysed mean difference was -5.75,
95%CI -8.63, -2.87 (on a scale ranging from 1 lowest to 5
highest decisional conflict; median standard deviation
13.25)[48]. Assuming a mean difference of -5.75 and
standard deviation 13.25, we would need approximately
84 women in each arm to demonstrate changes in deci-
sional conflict. The meta-analysis also showed that for
nine trials comparing decision aids and usual care, deci-
sion aids improved average knowledge scores by 18.75
points (out of 100) (95%CI 13.1 to 24.4, median stand-
ard deviation 20)[48]. To show such a difference, assum-
ing mean difference of 18.75 and standard deviation of
20, would require only 18 women in each arm. Because
we would like to be able to show differences in decisional
conflict if they exist, we have used the larger sample size
estimate. Although follow-up will be relatively short term,
there will inevitably be some loss to follow-up. To allow
for 10% loss to follow-up the sample size calculated
above (84) is inflated by 10% to give the effective sample
size of 92 women per arm and a total sample of 184 for
the trial. This sample size is different from our original
application for funding. Originally, we estimated a sam-
ple size of 310 women (155 in each arm). This was based
on results from a 1999 systematic review of only 2 trials of
decision aids versus usual care that had assessed deci-
sional conflict[35]. Subsequent to the submission (Janu-
ary 2001) and funding of this protocol (March 2002) the
systematic review was updated (2002) incorporating 6 tri-
als that assessed decisional conflict[48]. At that time we
revised the sample size estimate to incorporate the most
current research evidence available. Ethics approval was
obtained for the protocol amendment.
Data analysis
Analyses will be by intention to treat, including withdraw-
als and losses to follow-up. Study groups will be com-
pared in terms of baseline characteristics. As this is a
randomised trial, we would anticipate minimal differ-
ences in baseline characteristics. If however, important
differences are found, these potential confounders will be
adjusted for in the analysis of outcomes. For the primary
outcomes, the mean score for each measure for each
group will be compared using t-tests. If adjustment for
confounders is needed a multiple linear regression model
will be used. The secondary outcomes will be compared
using chi-square tests of significance for categorical data
and t-tests for continuous data. If adjustment for con-
founding is necessary logistic regression and multiple lin-
ear regression will be used respectively.
Interim analysis
An interim analysis will be conducted part way through
the study and the results will be reviewed by an independ-
ent Data Monitoring Committee. Specifically the inci-
dence of anxiety and decisional conflict in the two
randomised groups will be determined after the first 150
women have been enrolled and data have been collected.
If there is a significant increase in either of these outcomes
at p < 0.01 (1-tailed) with the decision aid, the trial will be
stopped. The trial will also be stopped of it is evident that
no clear outcome will be obtained.
Ethical considerations
We expect the project to provide ethical benefit. It is pos-
sible that some women may experience heightened anxi-
ety as a result of receiving the decision aid during its
evaluation by randomised trial. However, a systematic
review of decision aids found they improved knowledge
without increasing anxiety[33]. Nevertheless we will
measure anxiety levels at baseline and follow-up to docu-
ment any adverse effects. A trained research midwife will
interview all women and obtain written consent for the
trial. Women will be encouraged to discuss any concerns
or anxiety about the project with the research midwifeBMC Pregnancy and Childbirth 2004, 4:26 http://www.biomedcentral.com/1471-2393/4/26
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and/or with their usual antenatal care provider. Women
will be reassured that they are able to drop out of the study
at any time with no adverse effects on the management of
their pregnancy. Participation will require women to
complete brief self-report questionnaires during and after
pregnancy. Working through the decision aid will take ~
30 minutes and review of the decision and any outstand-
ing questions will be at a routine antenatal visit.
The study has been approved by the Central Sydney Area
Health Service Ethics Review Committee (Protocol no.
X01-0067) and the University of Sydney Human Ethics
Committee (Ref No. 3806).
Confidentiality and data security
Participants in the trial will be identified by a study
number only, with a master code sheet linking names
with numbers being held securely and separately from the
study data.
To ensure that all information is secure, data records will
be kept in a secure location at the University of Sydney
and accessible only to research staff. As soon as all follow-
up is completed the data records will be de-identified. De-
identified data will be used for the statistical analysis and
all publications will include only aggregated data.
The electronic version of the data will be maintained on a
computer protected by password. All hard copy patient
identifiable data and electronic backup files will be kept in
locked cabinets, which are held in a locked room accessed
only by security code and limited staff.
Data files will be stored for 7 (seven) years after comple-
tion of the project as recommended by the NHMRC. Dis-
posal of identifiable information will be done through the
use of designated bags and/or a shredding machine.
Outcomes and significance
This project will make an important contribution to a
largely neglected aspect of pregnancy care, assisting
informed participation by women in clinical decisions
that affect their pregnancy. Involvement in decision mak-
ing is a strong predictor of satisfaction with care in preg-
nancy and childbirth, yet there are only a few published
decision aids for maternity care. A decision aid for the
management of breech presentation is both timely and
practical as there is new evidence supporting planned CS,
dramatically altering the management options. Further,
the randomised trial will provide high quality evidence
about the effectiveness of the decision aid in supporting
shared clinical decision making during pregnancy. If suc-
cessful, the results of this project could be applied to
improve consumer information and participation in clin-
ical decisions across a wide spectrum of pregnancy care.
Finally, if the decision aid increases the utilisation of ECV,
in addition to reducing breech presentation and CS for
breech presentation (and the associated increased hospi-
talisation and potential morbidities), some women may
have more choice of where they give birth as breech pres-
entation precludes birth in birth centres and small rural
hospitals.
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